Altasciences Clinical Research Joins the Medrio Partner Program
SAN FRANCISCO (PRWEB) May 23, 2018 -- Altasciences Clinical Research, a full-service contract research organization (CRO) specializing in early phase clinical research, has joined the Partner Program at Medrio, a leading software as a service company providing cutting-edge eClinical tools for clinical trials. As a Medrio Partner, Altasciences will receive access to specialized training sessions customized to their needs, tailored customer service, and numerous other benefits that will further empower them to provide fast and top-quality data management services to their clients.
Altasciences has been a Medrio customer for over four years and, in that time, has used Medrio for their clinical data management in hundreds of studies. The company’s data managers cite the flexibility of the Medrio system as a major contributing factor for the success they’ve experienced, noting several features in particular:
• The ability to make database changes and deploy them live in minutes
• The ability to customize studies and create a library of reusable templates
• The EDC system’s user-friendly interface
• Offline data entry
“Altasciences entered into the Medrio Partner Program and chose their data management platform after extensive research”, commented Steve Mason, Executive Vice President, Site Operations, at Altasciences. “The system is user-friendly and easy for new users to navigate and respond to queries, and offers strong support from the Medrio helpdesk when needed. This has helped Altasciences achieve its internal goal of improving the overall level of customer service pertaining to data management. Overall, we consider this an extremely successful collaboration, and look forward to continuing to build our relationship with Medrio in the years to come.”
Mike Novotny, founder and CEO of Medrio, commented, “As a leading early phase CRO, Altasciences is perfectly positioned to benefit from the Phase I functionality we pride ourselves on here at Medrio. We’re honored to have them in the Partner Program, and are excited to keep providing our services to Altasciences in support of the important research they conduct.”
The Medrio Partner Program is a collaborative effort aligning Medrio’s sales, marketing, product, and development resources with trusted CROs and consultants to deliver superior customer experiences. The program aims to strengthen Medrio’s commitment to Customer Success by fostering closer communication with customers, helping partners win more business, and delivering numerous additional benefits.
About Medrio
Medrio is a leading healthcare technology company providing eClinical solutions including EDC, eSource, and ePRO for clinical research. Founded in 2005, the company's cloud-based software platform and mobile suite of products deliver fast, flexible, and easy-to-use tools for the collection and management of clinical data and patient reported outcome responses. Study sponsors and contract research organizations have used Medrio extensively across drug, device, diagnostic, and animal health trials. Medrio has extensive experience in all study phases and leads the market in early-phase trials. The company serves over 500 customers globally, with headquarters in San Francisco and offices in numerous domestic and international locations. For more information, please contact us or visit http://www.medrio.com.
About Altasciences Clinical Research
With over 25 years of experience and facilities in both the U.S. and Canada, Altasciences offers comprehensive Phase I/II drug development, with a flexible and customized approach, including the full array of required clinical support solutions. We continuously innovate to meet the industry’s demands and go above and beyond to address the ever-evolving and increasingly complex needs of sponsors, while maintaining a high level of patient engagement and safety. For more information, please visit http://www.altasciences.com.
Danielle Ostrovsky, Medrio, http://www.medrio.com, +1 410-302-9459, [email protected]
Share this article